BACKGROUND:Soy isoflavones are naturally occurring phytochemicals with weak estrogenic cellular effects. Despite numerous clinical trials of short-term isoflavone supplementation, there is a paucity of data regarding longer-term outcomes and safety. OBJECTIVE: Our aim was to evaluate the clinical outcomes of soy hypocotyl isoflavone supplementation in healthy menopausal women as a secondary outcome of a trial on bone health. DESIGN: A multicenter, randomized, double-blind, placebo-controlled 24-mo trial was conducted to assess the effects of daily supplementation with 80 or 120 mg aglycone equivalent soy hypocotyl isoflavones plus calcium and vitamin D on the health of 403 postmenopausal women. At baseline and after 1 and 2 y, clinical blood chemistry values were measured and a well-woman examination was conducted, which included a mammogram and a Papanicolaou test. A cohort also underwent transvaginal ultrasound measurements to assess endometrial thickness and fibroids. RESULTS: The baseline characteristics of the groups were similar. After 2 y of daily isoflavone exposure, all clinical chemistry values remained within the normal range. The only variable that changed significantly was blood urea nitrogen, which increased significantly after 2 y (P = 0.048) but not after 1 y (P = 0.343) in the supplementation groups. Isoflavone supplementation did not affect blood lymphocyte or serum free thyroxine concentrations. No significant differences in endometrial thickness or fibroids were observed between the groups. Two serious adverse events were detected (one case of breast cancer and one case of estrogen receptor-negative endometrial cancer), which was less than the expected population rate for these cancers. CONCLUSION: Daily supplementation for 2 y with 80-120 mg soy hypocotyl isoflavones has minimal risk in healthy menopausal women. This trial was registered at clinicaltrials.gov as NCT00665860.
RCT Entities:
BACKGROUND: Soy isoflavones are naturally occurring phytochemicals with weak estrogenic cellular effects. Despite numerous clinical trials of short-term isoflavone supplementation, there is a paucity of data regarding longer-term outcomes and safety. OBJECTIVE: Our aim was to evaluate the clinical outcomes of soy hypocotyl isoflavone supplementation in healthy menopausal women as a secondary outcome of a trial on bone health. DESIGN: A multicenter, randomized, double-blind, placebo-controlled 24-mo trial was conducted to assess the effects of daily supplementation with 80 or 120 mg aglycone equivalent soy hypocotyl isoflavones plus calcium and vitamin D on the health of 403 postmenopausal women. At baseline and after 1 and 2 y, clinical blood chemistry values were measured and a well-woman examination was conducted, which included a mammogram and a Papanicolaou test. A cohort also underwent transvaginal ultrasound measurements to assess endometrial thickness and fibroids. RESULTS: The baseline characteristics of the groups were similar. After 2 y of daily isoflavone exposure, all clinical chemistry values remained within the normal range. The only variable that changed significantly was blood ureanitrogen, which increased significantly after 2 y (P = 0.048) but not after 1 y (P = 0.343) in the supplementation groups. Isoflavone supplementation did not affect blood lymphocyte or serum free thyroxine concentrations. No significant differences in endometrial thickness or fibroids were observed between the groups. Two serious adverse events were detected (one case of breast cancer and one case of estrogen receptor-negative endometrial cancer), which was less than the expected population rate for these cancers. CONCLUSION: Daily supplementation for 2 y with 80-120 mg soy hypocotyl isoflavones has minimal risk in healthy menopausal women. This trial was registered at clinicaltrials.gov as NCT00665860.
Authors: P Alexandersen; A Toussaint; C Christiansen; J P Devogelaer; C Roux; J Fechtenbaum; C Gennari; J Y Reginster Journal: JAMA Date: 2001-03-21 Impact factor: 56.272
Authors: D Lee Alekel; Marta D Van Loan; Kenneth J Koehler; Laura N Hanson; Jeanne W Stewart; Kathy B Hanson; Mindy S Kurzer; C Theodore Peterson Journal: Am J Clin Nutr Date: 2009-11-11 Impact factor: 7.045
Authors: Carey E Gleason; Cynthia M Carlsson; Jodi H Barnet; Sarah A Meade; Kenneth D R Setchell; Craig S Atwood; Sterling C Johnson; Michele L Ries; Sanjay Asthana Journal: Age Ageing Date: 2008-12-02 Impact factor: 10.668
Authors: William W Wong; Richard D Lewis; Francene M Steinberg; Michael J Murray; Margaret A Cramer; Paula Amato; Ronald L Young; Stephen Barnes; Kenneth J Ellis; Roman J Shypailo; J Kennard Fraley; Karen L Konzelmann; Joan G Fischer; E O'Brian Smith Journal: Am J Clin Nutr Date: 2009-09-16 Impact factor: 7.045
Authors: Gertraud Maskarinec; Martijn Verheus; Francene M Steinberg; Paula Amato; Margaret K Cramer; Richard D Lewis; Michael J Murray; Ronald L Young; William W Wong Journal: J Nutr Date: 2009-03-25 Impact factor: 4.798
Authors: L Hooper; J J Ryder; M S Kurzer; J W Lampe; M J Messina; W R Phipps; A Cassidy Journal: Hum Reprod Update Date: 2009-03-19 Impact factor: 15.610
Authors: P B Clifton-Bligh; M-L Nery; R J Clifton-Bligh; S Visvalingam; G R Fulcher; K Byth; R Baber Journal: Eur J Clin Nutr Date: 2014-11-05 Impact factor: 4.016
Authors: S Hüser; S Guth; H G Joost; S T Soukup; J Köhrle; L Kreienbrock; P Diel; D W Lachenmeier; G Eisenbrand; G Vollmer; U Nöthlings; D Marko; A Mally; T Grune; L Lehmann; P Steinberg; S E Kulling Journal: Arch Toxicol Date: 2018-08-21 Impact factor: 5.153
Authors: D Lee Alekel; Ulrike Genschel; Kenneth J Koehler; Heike Hofmann; Marta D Van Loan; Bonnie S Beer; Laura N Hanson; Charles T Peterson; Mindy S Kurzer Journal: Menopause Date: 2015-02 Impact factor: 2.953
Authors: Jessica W Pawlowski; Berdine R Martin; George P McCabe; Linda McCabe; George S Jackson; Munro Peacock; Stephen Barnes; Connie M Weaver Journal: Am J Clin Nutr Date: 2015-08-05 Impact factor: 7.045
Authors: Felicia Cao; Linchao Lu; Steven A Abrams; Keli M Hawthorne; Allison Tam; Weidong Jin; Brian Dawson; Roman Shypailo; Hao Liu; Brendan Lee; Sandesh C S Nagamani; Lisa L Wang Journal: Hum Mol Genet Date: 2017-08-15 Impact factor: 6.150
Authors: Anne Cathrine Thorup; Max Norman Lambert; Henriette Strøm Kahr; Mette Bjerre; Per Bendix Jeppesen Journal: Evid Based Complement Alternat Med Date: 2015-07-21 Impact factor: 2.629